1. SARS-CoV-2 infection-acquired immunity waned after 1 year, but immune protection remained high beyond 1 year in those boosted with ...
1. In a retrospective cohort study of individuals who recovered from SARS-CoV-2, BNT162b2 vaccination decreased the risk of recurrent infection. ...
1. Widespread underlying SARS-CoV-2 seropositivity was observed in Gauteng province, South Africa, before the omicron wave. 2. Epidemiologic data demonstrated ...
1. Both the Johnson & Johnson-Janssen (JJJ) and mRNA boosters provided an acceptable safety profile and immunogenic response in healthcare ...
1. Homologous and heterologous booster vaccines had an acceptable safety profile in adults who completed a primary Covid-19 vaccine regimen. ...
1. mRNA booster vaccines for Covid-19 were highly effective against delta infection but less effective against omicron infection. 2. mRNA ...
1. The mRNA-1273 vaccine was shown to reduce the absolute risk of Covid-19-related outcomes in U.S. veterans compared to BNT162b2 ...
1. In this descriptive study, the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased across multiple age and ...
1. The mRNA Covid-19 vaccine, BNT162b2, has maintained its favorable safety profile through 6 months following vaccination. 2. Despite a ...
1. According to the mathematical model, a one-month delay in lifting all restrictions may have decreased peak hospital admissions by ...
